PEDIATRIC DRUG RESISTANT EPILEPSY: NEUROTECHNOLOGY FOR EPILEPSY IN THE NEWS

News coverage of drug resistant epilepsy (DRE) is an important resource to the public.

Media trends highlight new neurotechnology treatments for DRE and related societal issues.

OVERALL OPTIMISM
Neurotechnology media coverage has been positive over the last two decades.

<table>
<thead>
<tr>
<th>Year</th>
<th>2000-2009</th>
<th>2010-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>28%</td>
<td>61%</td>
</tr>
<tr>
<td>Balanced</td>
<td>20%</td>
<td>13%</td>
</tr>
<tr>
<td>Neutral</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Negative</td>
<td>2%</td>
<td>1%</td>
</tr>
</tbody>
</table>

COVERAGE OF TREATMENTS
Many types of neurotechnology are covered by the media.

Deep brain stimulation (38%)
Vagus nerve stimulation (30%)
Responsive neurostimulation (24%)
Transcranial magnetic stimulation (16%)
Unspecified (11%)

SOCIETAL ISSUES
Media coverage looks at ethical, legal, and social issues (ELSI) around epilepsy treatment.

ACCESS
- What barriers prevent treatment?
- How are costs covered?
- Which groups are left out?

SCHOOL
- What accommodations should schools provide?
- When is it safe to return to school after treatment?

LEARN MORE AND PROVIDE FEEDBACK AT WWW.NEUROETHICSCANADA.COM

NIH/NIMH 1RF1#MH117805